Innate Pharma (IPHA) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Innate Pharma is set to release its Q1 2026 TU results before the market opens on May 13, 2026 (7:30 AM ET); analysts expect ($0.3492) EPS and $2.716M in revenue (prior quarter: ($0.18) EPS, $2.41M revenue).
• Shares recently traded near $1.40 with a 52‑week range of $1.17–$2.63, and the stock carries a consensus rating of “Moderate Buy” with a $5.00 consensus price target amid mixed analyst opinions.
• Innate Pharma is a clinical‑stage biotech focused on antibody therapies that activate the innate immune system, with its lead program monalizumab (NKG2A) being developed in collaboration with AstraZeneca.

Innate Pharma (NASDAQ:IPHA - Get Free Report) is expected to release its Q1 2026 TU results before the market opens on Wednesday, May 13th. Analysts expect Innate Pharma to post earnings of ($0.3492) per share and revenue of $2.7160 million for the quarter. Investors may review the information on the company's upcoming Q1 2026 TU earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 7:30 AM ET.

Innate Pharma (NASDAQ:IPHA - Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($0.18) earnings per share for the quarter. The business had revenue of $2.41 million for the quarter. On average, analysts expect Innate Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Innate Pharma Stock Performance

Innate Pharma stock opened at $1.40 on Wednesday. Innate Pharma has a 52-week low of $1.17 and a 52-week high of $2.63. The firm has a 50 day moving average price of $1.47 and a two-hundred day moving average price of $1.71.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $5.00 price objective on shares of Innate Pharma in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Innate Pharma in a research report on Tuesday, April 21st. Finally, BTIG Research started coverage on Innate Pharma in a report on Thursday, March 12th. They set a "buy" rating and a $8.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.00.

Institutional Trading of Innate Pharma

Hedge funds have recently modified their holdings of the stock. Millennium Management LLC bought a new position in Innate Pharma during the fourth quarter worth $36,000. OLD Mission Capital LLC acquired a new stake in Innate Pharma in the fourth quarter worth $50,000. Finally, Jane Street Group LLC bought a new stake in Innate Pharma in the fourth quarter valued at $162,000. Institutional investors own 0.16% of the company's stock.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.